<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.104087</article-id><article-id pub-id-type="publisher-id">ACM-35176</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200400000_44623260.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  肿瘤相关性贫血儿童促红细胞生成素和肿瘤坏死因子α相关性研究
  Correlation between Erythropoietin and Tumor Necrosis Factor Alpha in Children with Malignant Tumor Anemia
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郝</surname><given-names>俊楠</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>徐</surname><given-names>武凤</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>魏</surname><given-names>敏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>玲珍</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>许</surname><given-names>倩文</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孙</surname><given-names>立荣</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院血液儿科，山东 青岛</addr-line></aff><aff id="aff3"><addr-line>齐鲁医院青岛分院儿科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>10</day><month>04</month><year>2020</year></pub-date><volume>10</volume><issue>04</issue><fpage>555</fpage><lpage>561</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   目的：本文旨在检测肿瘤相关性贫血(Cancer-Related Anemia, CRA)儿童促红细胞生成素(EPO)和肿瘤坏死因子(TNF)-α水平，以探讨两者及分别与血红蛋白(Hemoglobin, Hb)水平的相关性。方法：对恶性肿瘤(包括肿瘤贫血42例和肿瘤非贫血33例)及非肿瘤性贫血18例、健康查体儿童15组例采用化学发光法测定血清中EPO、TNF-α水平，分析EPO与Hb、TNF-α与Hb及EPO与TNF-α的相关性。结果：肿瘤贫血患儿血清EPO、TNF-α水平明显高于肿瘤非贫血及健康患儿(p &lt; 0.05)，肿瘤贫血患儿血清EPO与非肿瘤贫血比较差异无统计学意义(p &gt; 0.05)；肿瘤贫血组患儿血清EPO、TNF-α与Hb均呈负相关关系(r = −0.41、−0.48，p均&lt;0.05)，TNF-α与EPO及O/P相关性均无统计学意义(r = −0.16、−0.24，p均&gt;0.05)。结论：儿童CRA中内源性EPO对贫血的反馈性增生是充分的，TNF-α作为负向调控因子参与CRA，但其引起贫血的机制与抑制EPO产生无关。 Objective: This article aims to investigate the levels of erythropoietin (EPO) and tumor necrosis fac-tor (TNF)-α in children with tumor-associated anemia (CRA), and to investigate the relationship be-tween them and their correlation with hemoglobin (Hb) levels. Method: Patients (n = 108) with CRA or non-neoplastic hematological anemia and healthy control are selected. The chemiluminescence method was used to detect the serum level of EPO and TNF-α. The correlation between EPO and Hb, TNF-α and Hb, EPO and TNF-α is analyzed. Results: The levels of serum EPO and TNF-α in children with CRA were significantly higher than those in patients with non-anemia and healthy control (p &lt; 0.05). But there was no significant difference compared with non-neoplastic hematological children (p &gt; 0.05). Furthermore, the expected inverse linear relation between serum EPO and Hb levels was found in CRA, and so did the relation between serum TNF-α and Hb levels (r = −0.41, −0.48, p &lt; 0.05). But there was no correlation between TNF-α and EPO or O/P (r = −0.16, −0.24, p &gt; 0.05). Conclusion: The feedback hyperplasia of endogenous EPO to anemia in children’s CRA is sufficient. TNF-α is involved in CRA as a negative regulator, but its mechanism of causing anemia is not related to the inhibition of EPO production. 
 
</p></abstract><kwd-group><kwd>肿瘤相关性贫血，促红细胞生成素，肿瘤坏死因子肿瘤α，儿童, Tumor-Associated Anemia</kwd><kwd> Erythropoietin</kwd><kwd> Tumor Necrosis Factor-Alpha</kwd><kwd> Children</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>肿瘤相关性贫血儿童促红细胞生成素和肿瘤坏死因子α相关性研究<sup> </sup></title><p>郝俊楠<sup>1</sup>，徐武凤<sup>1</sup>，魏敏<sup>1</sup>，王玲珍<sup>1</sup>，许倩文<sup>2</sup>，孙立荣<sup>1*</sup></p><p><sup>1</sup>青岛大学附属医院血液儿科，山东 青岛</p><p><sup>2</sup>齐鲁医院青岛分院儿科，山东 青岛</p><disp-formula id="hanspub.35176-formula50"><graphic xlink:href="//html.hanspub.org/file/14-1571262x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2020年4月1日；录用日期：2020年4月15日；发布日期：2020年4月22日</p><disp-formula id="hanspub.35176-formula51"><graphic xlink:href="//html.hanspub.org/file/14-1571262x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：本文旨在检测肿瘤相关性贫血(Cancer-Related Anemia, CRA)儿童促红细胞生成素(EPO)和肿瘤坏死因子(TNF)-α水平，以探讨两者及分别与血红蛋白(Hemoglobin, Hb)水平的相关性。方法：对恶性肿瘤(包括肿瘤贫血42例和肿瘤非贫血33例)及非肿瘤性贫血18例、健康查体儿童15组例采用化学发光法测定血清中EPO、TNF-α水平，分析EPO与Hb、TNF-α与Hb及EPO与TNF-α的相关性。结果：肿瘤贫血患儿血清EPO、TNF-α水平明显高于肿瘤非贫血及健康患儿(p &lt; 0.05)，肿瘤贫血患儿血清EPO与非肿瘤贫血比较差异无统计学意义(p &gt; 0.05)；肿瘤贫血组患儿血清EPO、TNF-α与Hb均呈负相关关系(r = −0.41、−0.48，p均&lt;0.05)，TNF-α与EPO及O/P相关性均无统计学意义(r = −0.16、−0.24，p均&gt;0.05)。结论：儿童CRA中内源性EPO对贫血的反馈性增生是充分的，TNF-α作为负向调控因子参与CRA，但其引起贫血的机制与抑制EPO产生无关。</p><p>关键词 :肿瘤相关性贫血，促红细胞生成素，肿瘤坏死因子肿瘤α，儿童</p><disp-formula id="hanspub.35176-formula52"><graphic xlink:href="//html.hanspub.org/file/14-1571262x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/14-1571262x8_hanspub.png" /> <img src="//html.hanspub.org/file/14-1571262x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>不论肿瘤患者有无接受治疗，贫血都是常见的，被命名为肿瘤相关性贫血(CRA)。目前最大的调查研究之一，欧洲癌症贫血调查(ECAS) [<xref ref-type="bibr" rid="hanspub.35176-ref1">1</xref>] 中发现，15,367名接受化疗的患者中有39%在随后6个月被发现贫血(Hb &lt; 10.0 g/dL)。CRA的发病机理很复杂，通常很难识别，在大多数情况下是多因素的，并且与非CRA患者相比，有CRA病史的患者有可能会导致更加严重程度的贫血 [<xref ref-type="bibr" rid="hanspub.35176-ref2">2</xref>]。</p><p>CRA患者中有一部分没有明确病因，这种情况下的贫血多归为慢性病贫血(ACD) [<xref ref-type="bibr" rid="hanspub.35176-ref3">3</xref>]。潜在机制目前尚未完全清楚，但认为涉及肿瘤坏死因子(TNF)-α、白介素(IL)-1等炎性细胞因子 [<xref ref-type="bibr" rid="hanspub.35176-ref4">4</xref>]。这些细胞因子可能抑制内源性EPO生成，损害造血过程中铁利用并减少红细胞前体的增殖 [<xref ref-type="bibr" rid="hanspub.35176-ref5">5</xref>]。这种慢性炎症状态还会引起机体营养和代谢的变化，如体重减轻、低白蛋白血症、活性氧(ROS)增加等 [<xref ref-type="bibr" rid="hanspub.35176-ref6">6</xref>]。这些因素交互作用，也使机体产生对EPO的抵抗。因此，分析所有导致CRA的因素至关重要，尤其在开始可能加剧贫血的任何治疗之前。</p><p>本研究旨在明确儿童CRA血清EPO水平变化，有无EPO绝对或相对缺乏，以及EPO与TNF-α水平的相关性，明确有无以TNF-α为代表的炎症细胞因子的增高导致机体对EPO抵抗和钝化，分析CRA的发病机制。</p></sec><sec id="s4"><title>2. 对象与方法</title><sec id="s4_1"><title>2.1. 对象</title><p>收集2018年05月至2019年12月青岛大学附属医院医院血液儿科收治患儿为研究对象。恶性肿瘤组：75例，原发疾病为急性淋巴细胞白血病(ALL)、急性髓细胞白血病(AML)、淋巴瘤、肾母细胞瘤、神经母细胞瘤等，均符合相关疾病诊断标准，其中贫血组42(男26女16)例，年龄1~14 (7.2 &#177; 4.8)岁；未贫血组33 (男17女16)例，年龄1~13 (5.3 &#177; 2.7)岁；非肿瘤性贫血组：18 (男8女10)例，年龄1~15 (6.5 &#177; 4.2)岁，原发疾病为缺铁性贫血(IDA)、巨幼细胞性贫血等有非肿瘤性血液病；健康对照组：15 (男8女7)例，年龄1~10 (4.2 &#177; 3.8)岁，因健康查体于门诊就诊，无贫血且既往无慢性疾病及血液病史。以上所有患儿肾功能都正常。贫血的定义：6~59个月：&lt;11.0 g/dL；5~11岁：&lt;11.5 g/dL；12~16岁：&lt;12.0 g/dL [<xref ref-type="bibr" rid="hanspub.35176-ref7">7</xref>]。排除标准为：1) 病例资料极度不完整者；2) 伴有明显低氧血症；3) 有溶血及急、慢性失血，有贫血家族史；4) 合并其他慢性炎症性疾病如支气管哮喘、类风湿关节炎、炎症性肠病等；5) 目前有铁剂、维生素B12或叶酸治疗；6) 2周内有放化疗史，3月内有输血、ESAs及铁剂治疗史，近半年有手术史。分析EPO时采用的对照组：非肿瘤性贫血组18例(研究表明IDA患者EPO的反应增生能力正常)、健康对照组15例；分析TNF-α时对照组：健康对照组15例。本研究通过青岛大学附属医院医学伦理委员会批准。</p></sec><sec id="s4_2"><title>2.2. 方法</title><sec id="s4_2_1"><title>2.2.1. 标本采集与处理</title><p>抽取晨醒后患儿外周静脉血3~4 ml放置于添加了分离胶–促凝剂的试管中混匀，4℃，3000 r/min离心5 min，取上层血清置于−80℃冰箱中冷冻保存。</p></sec><sec id="s4_2_2"><title>2.2.2. 血清EPO、TNF-α检测</title><p>采用化学发光免疫分析法检测样本血清EPO、TNF-α浓度，试剂盒均购于德国Siemens公司。</p></sec><sec id="s4_2_3"><title>2.2.3. 血清EPO分析</title><p>取血清EPO的对数log10EPO (lgEPO)进行数值转换，对Hb和EPO有相关性的组别进行Hb与lgEPO的简单线性回归分析，得到回归方程(lgEPO = 截距 + 斜率*Hb)。应用回归方程计算相应Hb水平下lgEPO预计值，并计算实测lgEPO/预计lgEPO(简写：O/P)。贫血患者的O/P &lt; 0.80被视为EPO生成减弱 [<xref ref-type="bibr" rid="hanspub.35176-ref8">8</xref>]，正常对照为1.01 &#177; 0.11 [<xref ref-type="bibr" rid="hanspub.35176-ref9">9</xref>]。</p></sec><sec id="s4_2_4"><title>2.2.4. 统计学分析</title><p>计量资料的统计描述采用均数 &#177; 标准差进行表示。多组间比较先经方差分析后采用SNK-q检验，不满足方差齐性假设是应用校正的Welch方差分析后采用Games-Howell检验。计量资料之间相关关系的研究采用Pearson相关分析。p &lt; 0.05表示差异有统计学意义。应用SPSS24.0对数据进行统计分析。</p></sec></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 不同组别血清EPO水平变化</title><p>各组间血清EPO水平差异有统计学意义(F = 13.25, p &lt; 0.05)。肿瘤贫血组血清EPO水平[(341.73 &#177; 314.00) IU/L]明显高于肿瘤非贫血组EPO水平[(86.00 &#177; 14.62) IU/L]及健康对照组EPO水平[(32.78 &#177; 45.12) IU/L] (p均&lt;0.05)，但与非肿瘤贫血组[(235.26 &#177; 312.23) IU/L]比较差异无统计学意义。详见表1。</p></sec><sec id="s5_2"><title>3.2. 不同组别血清EPO水平与Hb的相关性分析</title><p>肿瘤贫血组血清EPO与Hb呈负相关关系(r = −0.41, p &lt; 0.01)；肿瘤非贫血组EPO与Hb相关性无统计学意义(r = −0.26, p &gt; 0.05)；非肿瘤贫血组EPO与 Hb相关性无统计学意义(r = −0.21, p &gt; 0.05)；健康对照组EPO与 Hb相关性无统计学意义(r = −0.14, p &gt; 0.05)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Serum EPO and TNF-α levels in different groups ( χ &#175; &#177; s </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >血红蛋白(g/L)</th><th align="center" valign="middle" >EPO (mIU/mL)</th><th align="center" valign="middle" >TNF-α (pg/ml)</th></tr></thead><tr><td align="center" valign="middle" >肿瘤贫血组</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >77.83 &#177; 15.01<sup>*</sup></td><td align="center" valign="middle" >314.00 &#177; 341.73<sup>*</sup></td><td align="center" valign="middle" >11.64 &#177; 9.19<sup>*</sup></td></tr><tr><td align="center" valign="middle" >肿瘤非贫血组</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >121.55 &#177; 9.31</td><td align="center" valign="middle" >86.00 &#177; 64.62</td><td align="center" valign="middle" >4.22 &#177; 2.52</td></tr><tr><td align="center" valign="middle" >非肿瘤贫血组</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >73.00 &#177; 20.95<sup>*</sup></td><td align="center" valign="middle" >235.26 &#177; 312.23<sup>*</sup></td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >健康对照组</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >126.12 &#177; 5.67</td><td align="center" valign="middle" >32.78 &#177; 45.12</td><td align="center" valign="middle" >3.16 &#177; 0.75</td></tr><tr><td align="center" valign="middle" >F</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >34.22</td><td align="center" valign="middle" >13.25</td><td align="center" valign="middle" >9.16</td></tr><tr><td align="center" valign="middle" >p</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.00</td><td align="center" valign="middle" >0.01</td><td align="center" valign="middle" >0.01</td></tr></tbody></table></table-wrap><p>表1. 不同组别血清EPO、TNF-α水平( χ &#175; &#177; s )</p><p>注：与健康对照组、肿瘤非贫血组比较，<sup>*</sup>p &lt; 0.05。</p><p>建立肿瘤品贫血组lgEPO与Hb的回归方程：lgEPO = 3.85 − 0.02Hb (R<sup>2</sup> = 0.62, p &lt; 0.05) (见图1)，lgEPO O/P 0.95 &#177; 0.28，有19.05% (8/42) O/P &lt; 0.8。</p><p>图1. 肿瘤贫血组lgEPO与Hb的线性回归线(黑色线)和90%预测期间(灰色线) (R<sup>2</sup> = 0.62, p &lt; 0.05)</p></sec><sec id="s5_3"><title>3.3. 不同组别血清TNF-α水平变化</title><p>各组间血清TNF-α水平差异有统计学意义(F = 9.16, p &lt; 0．05)。肿瘤贫血组血清TNF-α水平[(11.64 &#177; 9.19) pg/mL]明显高于肿瘤非贫血组TNF-α水平[(4.22 &#177; 2.52) pg/mL]及健康对照组TNF-α水平[(3.16 &#177; 0.75) pg/ml] (p均&lt;0.05) (血清TNF-α正常参考范围：0~8.10 pg/mL)。</p></sec><sec id="s5_4"><title>3.4. 不同组别血清TNF-α水平与Hb的相关性分析</title><p>肿瘤贫血组血清TNF-α与Hb呈负相关关系(r = −0.48, p &lt; 0.05)；肿瘤非贫血组血清TNF-α与Hb相关性无统计学意义(r = −0.25, p &gt; 0.05)；健康对照组血清TNF-α与Hb相关性无统计学意义(r = −0.19, p &gt; 0.05)。</p></sec><sec id="s5_5"><title>3.5. 不同组别血清TNF-α水平与EPO的相关性分析</title><p>肿瘤贫血组血清TNF-α与EPO及O/P相关性均无统计学意义(r = −0.16, p &gt; 0.05; r = −0.24, p &gt; 0.05)；肿瘤非贫血组血清TNF-α与EPO相关性均无统计学意义(r = −0.23, p &gt; 0.05)；健康对照组血清TNF-α与EPO相关性均无统计学意义(r = −0.21, p &gt; 0.05)。</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>贫血，其表现是外周血RBC数减少或Hb浓度降低，是影响肿瘤患者预后的独立危险因素 [<xref ref-type="bibr" rid="hanspub.35176-ref10">10</xref>]。恶性肿瘤患儿贫血严重程度可能与多种变量相关联，包括患儿的年龄、疾病的程度、性质和持续治疗的时间等。还有学者提出特定方面的营养缺乏、骨髓的肿瘤浸润及并发感染等因素也参与了贫血的发病过程 [<xref ref-type="bibr" rid="hanspub.35176-ref11">11</xref>]。这些因素对于贫血是单独还是协同发挥作用目前尚不清楚。</p><p>EPO是一种调控红细胞生成的糖蛋白。据文献报道，肾功能正常的贫血患者EPO合成机制尚完整,血清EPO水平增高，其贫血机制与EPO水平无关 [<xref ref-type="bibr" rid="hanspub.35176-ref12">12</xref>]。将单纯IDA患者做正常参照，成人CRA患者的EPO水平相对于前者是低的，说明CRA患者的EPO对贫血的反应是钝化的 [<xref ref-type="bibr" rid="hanspub.35176-ref13">13</xref>]。故在本研究中，纳入包括IDA患者在内的其他非肿瘤性贫血病例。与EPO水平正常的健康对照组相比，CRA患者和非肿瘤性贫血患者EPO均是明显升高的，但两者比较无差异，不存在EPO的钝化，与Corazza等 [<xref ref-type="bibr" rid="hanspub.35176-ref14">14</xref>] 的研究结果相似。但非肿瘤性贫血病例除5例IDA外，还有其他类型的贫血，其贫血对EPO的反应是否一致有待进一步研究。</p><p>有研究表明ALL贫血患儿血清EPO水平和Hb水平之间存在反比关系，并且可以通过反馈方式调节Hb水平 [<xref ref-type="bibr" rid="hanspub.35176-ref15">15</xref>]。本研究中在肿瘤贫血组中发现了这种反比关系，并对EPO和Hb进行线性回归分析得到O/P，超过80%的病例O/P &gt; 0.8，再次证明患儿EPO对贫血反应无钝化 [<xref ref-type="bibr" rid="hanspub.35176-ref16">16</xref>]。本研究纳入对象均为肾功能正常者，其中有原发部位在肾脏的肿瘤如肾母细胞瘤患者5例，在贫血状态下有4例血清EPO水平是升高的，另有1例为一侧肾切除术后，其EPO无升高，O/P &lt; 0.8，其贫血原因不能简单的归为EPO生成的缺乏，肾切除术可能与其发病相关。虽然CRA中EPO反馈性升高，但贫血无纠正。慢性炎症及营养代谢障碍对红细胞生成的抑制作用，可能与之有关。</p><p>ACD又名炎症性贫血，是由慢性感染、恶性肿瘤和自身免疫性疾病等因素引起，缓解期贫血可能是ACD的一种表现形式 [<xref ref-type="bibr" rid="hanspub.35176-ref17">17</xref>]。这种炎症状态表现为CRP升高、体重减轻、低白蛋白血症和EPO抵抗性贫血，并涉及免疫、营养和代谢多种发病机制 [<xref ref-type="bibr" rid="hanspub.35176-ref18">18</xref>]。炎症本身也可干扰营养状态，继而使贫血加重。炎症细胞因子如IL-1和TNF-α等，既可以抑制红系祖细胞的增殖，也钝化了血清EPO对Hb下降的正常反应，参与贫血的发生 [<xref ref-type="bibr" rid="hanspub.35176-ref19">19</xref>]。TNF-α与炎症和肿瘤密切相关，在多种肿瘤微环境中均有表达，并被归类为肿瘤促进剂 [<xref ref-type="bibr" rid="hanspub.35176-ref20">20</xref>]。本研究发现CRA中TNF-α与Hb两者呈负相关，说明TNF-α抑制了红细胞的生成。同时，TNF-α也可直接抑制EPO的生成 [<xref ref-type="bibr" rid="hanspub.35176-ref21">21</xref>]。但也有研究表明EPO可通过巨噬细胞诱导一氧化氮合成酶抑制TNF-α、IL-6等炎性因子的形成 [<xref ref-type="bibr" rid="hanspub.35176-ref22">22</xref>]。但Tsopra等 [<xref ref-type="bibr" rid="hanspub.35176-ref23">23</xref>] 在慢性淋巴细胞白血病中的证实，贫血的发生独立于EPO生成和刺激，可能是TNF-α对红细胞生成早期红系发育的直接抑制作用导致。本研究对CRA中EPO及O/P与TNF-α进行分析，均未发现相关性，与以上研究结果一致。</p><p>综上所述，在儿童肿瘤贫血患儿中，EPO和TNF-α均参与贫血的发生。内源性EPO对贫血的反馈性增生是充分的，TNF-α作为负向调控因子参与贫血的机制与抑制EPO产生无关，与成人研究结果相反 [<xref ref-type="bibr" rid="hanspub.35176-ref24">24</xref>]。有必要进行更多研究了解儿童CRA中EPO和TNF-α之间的分子调节机制，更好地了解CRA的发病机制指导预防和治疗。</p></sec><sec id="s7"><title>文章引用</title><p>郝俊楠,徐武凤,魏 敏,王玲珍,许倩文,孙立荣. 肿瘤相关性贫血儿童促红细胞生成素和肿瘤坏死因子α相关性研究Correlation between Erythropoietin and Tumor Necrosis Factor Alpha in Children with Malignant Tumor Anemia[J]. 临床医学进展, 2020, 10(04): 555-561. https://doi.org/10.12677/ACM.2020.104087</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.35176-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Ludwig, H., Van Belle, S., Barrett-Lee, P., et al. (2004) The European Cancer Anaemia Survey (ECAS): A Large, Multinational, Prospective Survey Defining the Prevalence, Incidence, and Treatment of Anaemia in Cancer Patients. European Journal of Cancer, 40, 2293-2306. &lt;br&gt;https://doi.org/10.1016/j.ejca.2004.06.019</mixed-citation></ref><ref id="hanspub.35176-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Rodgers, G.M., Becker, P.S., Blinder, M., et al. (2012) Cancer and Chemotherapy-Induced Anemia. Journal of the National Compre-hensive Cancer Network, 10, 628-653. &lt;br&gt;https://doi.org/10.6004/jnccn.2012.0064</mixed-citation></ref><ref id="hanspub.35176-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Cullis, J. (2013) Anaemia of Chronic Disease. Clinical Medicine, 13, 193-196.  
&lt;br&gt;https://doi.org/10.7861/clinmedicine.13-2-193</mixed-citation></ref><ref id="hanspub.35176-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Macciò, A. and Madeddu, C. (2012) Inflammation and Ovarian Cancer. Cytokine, 58, 133-147.  
&lt;br&gt;https://doi.org/10.1016/j.cyto.2012.01.015</mixed-citation></ref><ref id="hanspub.35176-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Bode, J.G., Albrecht, U., Hussinger, D., et al. (2012) Hepatic Acute Phase Proteins—Regulation by IL-6- and IL-1-Type Cytokines Involving STAT3 and Its Crosstalk with NF-κB-Dependent Signaling. European Journal of Cell Biology, 91, 496-505. &lt;br&gt;https://doi.org/10.1016/j.ejcb.2011.09.008</mixed-citation></ref><ref id="hanspub.35176-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Kundu, J.K. and Surh, Y.J. (2012) Emerging Avenues Linking Inflammation and Cancer. Free Radical Biology &amp; Medicine, 52, 2013-2037. &lt;br&gt;https://doi.org/10.1016/j.freeradbiomed.2012.02.035</mixed-citation></ref><ref id="hanspub.35176-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">王卫国, 孙锟, 等. 儿科学[M]. 第9版. 北京: 人民卫生出版社, 2018: 331-332.</mixed-citation></ref><ref id="hanspub.35176-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Cazzola, M. (2003) Erythropoietin Therapy: Need for Rationality and Active Surveil-lance. Haematologica, 88, 601-605.</mixed-citation></ref><ref id="hanspub.35176-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Manfred, N., et al. (2016) Iron Deficiency or Anemia of Inflammation: Differ-ential Diagnosis and Mechanisms of Anemia of Inflammation. Wiener Medizinische Wochenschrift, 166, 411-423.  
&lt;br&gt;https://doi.org/10.1007/s10354-016-0505-7</mixed-citation></ref><ref id="hanspub.35176-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Victor, P., Paitan, A., Cindy, L., et al. (2018) Anemia as a Prognostic Factor in Cancer Patients. La Revista Peruana de Medicina Experimental y Salud Pública, 35, 250-258. &lt;br&gt;https://doi.org/10.17843/rpmesp.2018.352.3171</mixed-citation></ref><ref id="hanspub.35176-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Grotto, H.Z.W. (2008) Anaemia of Cancer: An Overview of Mechanisms Involved in Its Pathogenesis. Medical Oncology, 25, 12-21. &lt;br&gt;https://doi.org/10.1007/s12032-007-9000-8</mixed-citation></ref><ref id="hanspub.35176-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Nayak-Rao, S. and Mccormick, B. (2013) Erythropoietin Use in CKD Patients with Cancer: To Tread with Caution? Journal of Nephrology, 26, 829-835. &lt;br&gt;https://doi.org/10.5301/jn.5000316</mixed-citation></ref><ref id="hanspub.35176-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Blindar, V., Zubrikhina, G., Davydova, T., et al. (2019) Development of Strategic Approaches to Modern Diagnosis of Anemic Syndrome in Patients with Breast Cancer. Kliniceskaja Laboratornaja Diagnostika, 64, 210-215.  
&lt;br&gt;https://doi.org/10.18821/0869-2084-2019-64-4-210-215</mixed-citation></ref><ref id="hanspub.35176-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Corazza, F., Beguin, Y., Bergmann, P., et al. (1998) Anemia in Children with Cancer Is Associated with Decreased Erythropoietic Activity and Not with Inadequate Erythropoietin Production. Blood, 92, 1793-1798.  
&lt;br&gt;https://doi.org/10.1182/blood.V92.5.1793</mixed-citation></ref><ref id="hanspub.35176-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Steele, M.G. and Narendran, A. (2012) Mechanisms of Defective Erythropoiesis and Anemia in Pediatric Acute Lymphoblastic Leukemia (ALL). Annals of Hematology, 91, 1513-1518. &lt;br&gt;https://doi.org/10.1007/s00277-012-1475-5</mixed-citation></ref><ref id="hanspub.35176-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Tisi, M.C., Bozzoli, V., Giachelia, M., et al. (2014) Anemia in Diffuse Large B-Cell Non-Hodgkin Lymphoma: The Role of Interleukin-6, Hepcidin and Erythropoietin. Leukemia &amp; Lymphoma, 55, 270-275.  
&lt;br&gt;https://doi.org/10.3109/10428194.2013.802314</mixed-citation></ref><ref id="hanspub.35176-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Demarmels Biasiutti, F. (2010) Anemia of Chronic Disorder: Pathogenesis, Clinical Presentation and Treatment. Therapeutische Umschau Revue Thérapeutique, 67, 225-228. &lt;br&gt;https://doi.org/10.1024/0040-5930/a000041</mixed-citation></ref><ref id="hanspub.35176-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Maccio, A., Madeddu, C., Gramignano, G., et al. (2015) The Role of Inflammation, Iron, and Nutritional Status in Cancer-Related Anemia: Results of a Large, Prospective, Observational Study. Haematologica, 100, 124-132.  
&lt;br&gt;https://doi.org/10.3324/haematol.2014.112813</mixed-citation></ref><ref id="hanspub.35176-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Buck, I., Morceau, F., Grigorakaki, C., et al. (2009) Linking Anemia to Inflammation and Cancer: The Crucial Role of TNFα. Biochemical Pharmacology, 77, 1572-1579. &lt;br&gt;https://doi.org/10.1016/j.bcp.2008.12.018</mixed-citation></ref><ref id="hanspub.35176-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Atretkhany, K.N., Gogoleva, V.S. and Drutskaya, M.S. (2020) Distinct Modes of TNF Signaling through Its Two Receptors in Health and Disease. Journal of Leukocyte Biology, 1-13. &lt;br&gt;https://doi.org/10.1002/JLB.2MR0120-510R</mixed-citation></ref><ref id="hanspub.35176-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Ek, T., Mellander, L. and Abrahamsson, J. (2005) Interferon γ and Tumour Necrosis Factor α in Relation to Anaemia and Prognosis in Childhood Cancer. Acta Paediatrica, 94, 435-437.  
&lt;br&gt;https://doi.org/10.1111/j.1651-2227.2005.tb01914.x</mixed-citation></ref><ref id="hanspub.35176-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Nairz, M., Sonnweber, T., Schroll, A., et al. (2012) The Pleiotropic Effects of Erythropoietin in Infection and Inflammation. Microbes &amp; Infection, 14, 238-246. &lt;br&gt;https://doi.org/10.1016/j.micinf.2011.10.005</mixed-citation></ref><ref id="hanspub.35176-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Tsopra, O.A., Ziros, P.G., Lagadinou, E.D., et al. (2009) Dis-ease-Related Anemia in Chronic Lymphocytic Leukemia Is Not Due to Intrinsic Defects of Erythroid Precursors: A Pos-sible Pathogenetic Role for Tumor Necrosis Factor-Alpha. Acta Haematologica, 121, 187-195. &lt;br&gt;https://doi.org/10.1159/000220331</mixed-citation></ref><ref id="hanspub.35176-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">刘东芳, 张成侠, 冯志刚, 等. 铁调素、IFN-γ、TNF-α等负调控因子对肿瘤性贫血患者红系增生的影响[J]. 医学临床研究, 2015(10): 1940-1942.</mixed-citation></ref></ref-list></back></article>